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Abstract
Purpose Assessment of the absorption, metabolism and
excretion of [
14C]-lenalidomide in healthy male subjects
following a single oral dose.
Methods Six healthy male subjects were administered a
single 25 mg oral suspension dose of [
14C]-lenalidomide.
Blood (plasma), semen and excreta were collected. Mass
balance assessments were done by radioactivity measure-
ments. Metabolite proﬁling and quantitation were accom-
plished using liquid chromatography with mass
spectrometric and radiochemical detection.
Results [
14C]-Lenalidomide was rapidly absorbed (Tmax
0.77–1.0 h), and the levels declined with a terminal half-
life of approximately 3 h, with similar proﬁles for total
blood and plasma radioactivity as well as plasma lenalid-
omide. The whole blood to plasma radioactivity exposure
levels were comparable, suggesting equal distribution
between plasma and blood cells. On average, 94% of the
administered radioactivity was recovered within 10 days,
with [88% recovered within 24 h. Urinary excretion was
the primary route of elimination (90% of radioactive dose),
with minor amounts excreted in feces (4%). Semen
contained a small amount of the radioactive dose
(0.0062%). Lenalidomide was the primary radioactive
component in plasma (92% of the [
14C]-area under the
concentration–time curve) and urine ([90% of the radio-
activity in urine). The remaining radioactivity was com-
posed of primarily two metabolites: 5-hydroxy-
lenalidomide and N-acetyl-lenalidomide, each accounting
for less than 5% of the total radioactivity as well as lena-
lidomide levels in plasma and excreta.
Conclusions In summary, following oral administration,
lenalidomide is highly absorbed and bioavailable, metab-
olized minimally, and eliminated predominantly via uri-
nary excretion in the unchanged form in humans.
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Introduction
Lenalidomide (3-(40aminoisoindoline-10-one)-1-piperidine-
2,6-dione; Revlimid
; Fig. 1) is an oral immunomodula-
tory drug (IMiD
)[ 1], with antineoplastic, antiangiogenic
and anti-inﬂammatory properties [2, 3]. It has been used for
the treatment of transfusion-dependent anemia due to low-
or intermediate-risk myelodysplastic syndromes (MDS)
associated with a deletion 5q cytogenetic abnormality with
or without additional cytogenetic abnormalities [4, 5], and
in combination with dexamethasone for the treatment of
multiple myeloma (MM) patients who have received at
least one prior therapy [6, 7]. Lenalidomide, as a single
agent or in combination with other agents, is also being
evaluated for the treatment of newly diagnosed MM,
chronic lymphocytic leukemia, non-Hodgkin’s lymphoma
and certain solid tumors [8–12].
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function, lenalidomide displays linear pharmacokinetics.
The plasma exposure of lenalidomide is proportional to
dose up to 400 mg and it does not accumulate with mul-
tiple doses [13, 14]. The mean terminal elimination half-
life (t1/2) was approximately 3–4 h in clinically relevant
dose range (5–50 mg) [13, 14]. Excretion of the unchanged
parent in urine is the predominant clearance mechanism of
lenalidomide, accounting for approximately 84% of the
dose [15].
Incubation of lenalidomide with human liver micro-
somes, recombinant-CYP isozymes and human hepatocytes
did not result in Phase I or Phase II metabolism [16]. Le-
nalidomide undergoes hydrolysis in human plasma, with an
in vitro half-life of approximately 8 h, due to hydrolytic
cleavage of glutarimide amide bonds (unpublished data).
Although metabolism data on lenalidomide have been
collected from in vitro studies, a thorough investigation of
the metabolism of lenalidomide has not yet been conducted
in vivo in humans.
The purposes of this study were to characterize the
disposition of [
14C]-lenalidomide in humans and to identify
metabolites in circulation and excreta after a single oral
suspension dose. The results of this study will help deter-
mine whether lenalidomide exposure is subject to alteration
in patients with hepatic insufﬁciency, potential for drug–
drug interactions during polypharmacy, and the potential
for the exposure of female partner during a heterosexual
intercourse when the male partner is on lenalidomide
therapy.
Methods
Materials
The speciﬁc activity, chemical purity and radiochemical
purity of [
14C]-lenalidomide (synthesized by Girindus
Solvay Organics for Celgene Corporation) used for the
preparation of the dosage formulation in this study were
approximately 200.9 lCi/mg (52.43 mCi/mmol), 99.8 and
99.8%, respectively. The study dosage form was
manufactured by Girindus Solvay Organics (for Celgene
Corporation) in individual 20 ml clear glass scintillation
vials containing approximately 25 mg of preweighed
powder, comprising a mixture of racemic [
14C]-lenalido-
mide and racemic unlabeled lenalidomide powders. The
actual radioactivity contained in each dosage was approx-
imately 85 lCi, with a speciﬁc activity of approximately
3.4 lCi/mg.
Study design and subjects
This was an open-label, single-center, single oral dose
study in healthy male subjects. The study was conducted at
Quintiles Phase I Study Center (Overland Park, Kansas).
The study protocol and Informed Consent Form were
approved by the Institution Review Board (Lenexa, Kan-
sas) and Radiation Safety Committee at Quintiles Phase I
Services prior to study initiation.
Subjects were eligible for the study if they met the
following criteria: were male; aged 18–45 years; weighed
60–100 kg, with a body mass index of 19–30 kg/m
2; were
healthy as determined by medical history, physical exam-
ination, 12-lead electrocardiogram (ECG), serum bio-
chemistry, hematology and urinalysis. All subjects must
agree to use a reliable method(s) of contraception during
study and for at least 28 days after study. Subjects were
excluded, if they had the following conditions: positive
results to the tests for drugs of abuse, alcohol or cotinine;
positive results for hepatitis B surface antigen, hepatitis C
antibody or human immunodeﬁciency virus (HIV) anti-
body; exposure to excess radiation or participation in a
study involving radioisotopes within the previous
12 months; current or a history of vasectomy, vasoligation,
an undescended testicle(s) or ejaculation problems.
The subjects entered the study center on the day prior to
dosing and remained at the center for up to 10 days fol-
lowing dosing or until the total radioactivity recovered in
urine and fecal samples from two consecutive days was
B1% of the administered radioactive dose. All subjects
were asked to abstain from any study-unrelated sexual
activities including self-masturbation from 72 h before
dosing until after the last semen sample was taken.
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123Safety assessments
Physical examination, clinical laboratory tests (hematol-
ogy, serum chemistry and urinalysis) and 12-lead ECG
were performed at the selected times before and after the
administration of the study drug. All subjects were moni-
tored throughout the study for adverse events and vital
signs and for the use of concomitant medications. Adverse
events were evaluated by the investigator as to their
intensity, seriousness and relationship to study drug.
Treatment
Within 15 min prior to dosing, 15 ml of distilled water was
added to the dosage vial, and the vial was sonicated for
5 min to obtain a homogenous suspension of the study
drug. Within 10 min of completion of sonication, the
subject ingested the drug suspension. The dosing vial was
rinsed with 15 ml of distilled water, sonicated for 1 min
and the rinse ingested by the subject. This procedure was
repeated twice more (i.e., total 3 rinses). Following
ingesting the three rinses, the subject drank an additional
180 ml of water. The entire procedure for dosing each
subject (from ingestion of the initial drug suspension to
ingestion of the ﬁnal 180 ml water) was completed within
no more than 5 min. All dosing vials were saved for the
measurement of residual radioactivity. The actually
administered mass of dose and radioactivity (lCi) were
recorded.
Subjects were fasted for at least 8 h before dosing and
for 4 h after dosing. Water was not allowed for 2 h before
dosing and for 4 h after dosing. To aid in daily bowel
movements, subjects received high-ﬁber meals and a stool
softer (Fibercon in each evening) from check-in until dis-
charge from the study center.
Biologic sample collections
Whole blood samples were collected into EDTA tubes at
predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96,
120, 144 and 168 h postdose. At each time point, a portion
of the blood sample was saved for counting the total
radioactivity in the whole blood and the remaining blood
was used to prepare plasma. Within 30 min of collection,
blood samples were centrifuged at 4C to obtain plasma,
which were stored at -70C until analysis.
Urine were collected as voided at predose (spot collec-
tion), pooled postdosing over the intervals of 0–4, 4–8,
8–12, 12–24 h on Day 1, and over intervals of 24 h on
Days 2–10. The total volume of urine collected over each
interval was recorded. Subsequently, an aliquot of urine
taken, acidiﬁed with an equal volume of Sorenson’s citrate
buffer (pH 1.5) and stored at 4C (for counting radioac-
tivity) or -70C until assayed.
Feces were collected as individual bowel movements at
predose and pooled postdosing over 24 h intervals for up to
10 days. The fecal samples were homogenized to a slurry
(using 4 volumes, by weight, of pH 1.5 Sorensen’s buffer),
and the homogenized samples were stored at -70C until
assayed.
Semen samples were collected during screening (base-
line sample), between 2 and 3 h postdose, and between 72
and 73 h postdose. To avoid contamination with urinary
[
14C]-lenalidomide/metabolites in the semen sample col-
lected during 2 to 3 h postdose, the subject was asked to
empty his bladder immediately prior to dosing and to
produce this semen sample before collection of any urine
for the ﬁrst postdose collection interval. Semen was ejac-
ulated, by masturbation, into a container. Within 15 min of
collection, the semen was mixed with two volumes, by
weight, of pH 1.5 Sorensen’s citrate buffer to give a ﬁnal
semen/buffer ratio of 1:2 [w/w]. The acidiﬁed semen
samples were stored at -70C until assayed.
Determination of radioactivity
The radioactivity was measured by liquid scintillation
counter (Beckman LS6000SC or LS6500) either for 20 min
or until the 2-sigma error is less than or equal to 2%,
whichever came ﬁrst. Duplicate aliquots for plasma and
urine samples were directly counted for radioactivity in
Ultima Gold scintillation cocktail (Packard). Duplicate
aliquots for whole blood, fecal homogenates and semen
samples were combusted in a Packard model 307 oxidizer.
After combustion, the resulting [
14C]-carbon dioxide was
collected into CarboSorb and Permaﬂuor (Packard Instru-
ment Co.) and counted. The mean percent recoveries of
quality control samples were within 100 ± 15% for all
matrices. The amount of radioactivity (dpm) in whole
blood, plasma, urine, feces and semen were converted to
equivalent concentrations of lenalidomide (ngEq/g, ngEq/
ml or lgEq/g) based on the speciﬁc activity of the
administered compound (3.4 lCi/mg).
Determination of lenalidomide
Plasma samples were analyzed for lenalidomide concen-
trations by a validated achiral liquid chromatography-tan-
dem mass spectrometry (LC–MS/MS) method. Brieﬂy,
plasma samples, with
13C5-lenalidomide as the internal
standard, were processed by combining with acidiﬁed
acetonitrile. The supernatants were processed, and the
chromatographic separation was achieved by high-perfor-
mance liquid chromatography (HPLC) using a Monochrom
C18 column (5 l, 100 9 4.6 mm) operated at ambient
Cancer Chemother Pharmacol (2012) 69:789–797 791
123temperature. The gradient mobile phase consisted of 0.1%
formic acid in water and 0.1% formic acid in acetonitrile at
a ﬂow rate of 0.8 ml/min with a run time of 5.5 min.
Detection was performed by an AB Sciex API 4000 mass
spectrometer conﬁgured with electro spray ionization in the
positive ion mode. Data were acquired by multiple-reaction
monitoring of mass transition pairs at m/z of 260.3[149.1
for lenalidomide and 265.3[149.1 for the internal stan-
dard. The lenalidomide standard curve was linear from 5 to
1,000 ng/ml, with a lower limit of quantitation of 5 ng/ml.
Pharmacokinetic analysis
Total radioactivity excreted in urine, feces and semen were
converted to percentage of the actually administered
radioactive dose (% dose). The total recovery of radioac-
tivity was computed as the sum of the cumulative excretion
(as % dose) in urine, feces and semen.
Standard pharmacokinetic parameters were estimated
from the lenalidomide concentration versus time proﬁle or
the blood and plasma radioactive concentration equivalents
versus time proﬁles by established noncompartmental
methods using WinNonlin Professional Version 4.1b
(Pharsight Corporation, Mountain View, CA) or SAS

Version 8.2 (SAS Institute, Cary, NC).
The distribution of radioactivity in red blood cells as
percentage of the whole blood radioactivity was estimated
by the following equation:
Cwb   1   Ht
100

  Cp
Cwb
  100%
where Cwb and Cp were the radioactive concentration
equivalent in whole blood and plasma, respectively, and Ht
was the mean value of the hematocrit obtained from Day 0
(baseline) and follow-up.
Metabolite proﬁling
A total of six pooled inter-subject plasma samples were
prepared before the extraction by combining equal volume
(2 ml) of plasma from the six subjects by time points. The
prepared pooled plasma samples were acidiﬁed and sub-
jected to solid phase extraction using C-18 Strata SEP Pak
column; the eluates were dried under a nitrogen stream,
and the residue was reconstituted with 0.1% aqueous acetic
acid for further analysis. Urine samples were centrifuged to
sediment particulate matter, and the supernatants were
analyzed without further processing. Six individual semen
samples collected at 2–3 h postdose (one from each sub-
ject) were analyzed after processing in a manner similar to
plasma samples described above. Based on the radioac-
tivity in the fecal homogenates, selected fecal samples
from each subject were used for metabolic proﬁling.
Aliquots of fecal homogenates were combined with 0.1%
acetic acid in acetone, vortexed and centrifuged at
4,500–5,000 rpm and 4C for 10 min. The supernatant was
transferred to a fresh tube, and the extraction procedure
was repeated twice, and the pooled supernatants were
concentrated under nitrogen stream to a ﬁnal volume of
0.5–2 ml.
Liquid chromatography with radiochemical detection
was performed for quantitative analysis of [
14C]-lenalido-
mide and its metabolites. Separations were achieved using
a Varian Monochrom 5 l, C18, 4.6 9 100 mm, with a
gradient mobile phase of A (0.1% acetic acid in water) and
B (0.1% acetic acid in acetonitrile) at a ﬂow rate of 1 ml/
min and a run length of 55 min.
Metabolite identiﬁcation was accomplished by mass
spectrometry with API 4000 Q-trap spectrometer (AB
Sciex, Foster City, CA) run in two modes, ESI (electro
spray ionization) or APCI (atmospheric pressure chemical
ionization) in positive ionization mode. Accurate mass
measurements were performed using LTQ OrbiTrap
(Thermo, San Jose, CA). The deﬁnitive structural assign-
ments were accomplished by the comparison of chro-
matographic retention times, the molecular masses and the
fragmentation patterns of parent and metabolites compared
to their respective synthetic standards.
Results
Subjects and dosing
The 6 healthy male subjects who participated in the study
had a mean age of 29.7 years (range: 20–42 years), a mean
height of 178.92 cm (range: 173.4–181.5 cm), a mean
weight of 83.95 kg (range: 77.7–91.2 kg) and a mean BMI
of 26.22 kg/m
2 (range: 24.1–27.8 kg/m
2). Three subjects
(50%) were Black and 3 subjects (50%) were White. The
mean (±SD) dose administered was 84.6 ± 0.47 lCi of
the [
14C]-radioactivity and 24.9 ± 0.12 mg of
lenalidomide.
Safety
There were no deaths, serious adverse events or discon-
tinuations from the study due to adverse events. Overall, 5
adverse events were reported by 4 subjects (66.7%) after
dosing. Gastrointestinal disorders (hard feces, gastro-
esophageal reﬂux and stomach discomfort), reported by 3
(50%) of the 6 subjects, were the most common AE in this
study. Of the 5 adverse events, only the event of hard feces
was assessed by the investigator as having a suspected
relationship to study medication. All the adverse events
were assessed as mild in intensity by the investigator and
792 Cancer Chemother Pharmacol (2012) 69:789–797
123all resolved prior to study conclusion. There were no drug-
related changes in clinical laboratory results, vital signs,
ECG values and physical examinations.
Mass balance
The total recovery of the radioactivity over 10 days
averaged 94.3 ± 2.9% (range: 90.5–97.2%) of the
administered dose, with majority (88.5%) of the radioac-
tivity recovered in 24 h postdose (Fig. 2, Table 1). A total
of 90.3 ± 3.0% (range: 87.0–94.6%) of dose was recov-
ered in urine, which indicates the oral absorption of le-
nalidomide was high. Furthermore, urinary excretion of
the radioactivity was rapid, with approximately 84% of
the administered dose recovered in urine during the ﬁrst
12 h and 88.5% recovered during 24 h (Fig. 2). In con-
trast, mean total fecal elimination of radioactivity
accounted for only 3.95 ± 1.94% of the dose. Most fecal
excretion was completed by Day 4 (96 h). Only a very
small amount of the radioactivity (0.0062% of the dose;
1.479 lg equivalent of [
14C]-lenalidomide) was recovered
from semen.
Pharmacokinetics
The pharmacokinetic parameters are summarized in
Table 2. The mean concentrations for the total radioactiv-
ity in plasma and whole blood were comparable to that for
the parent compound in plasma. For all the three measures,
namely total radioactivity in blood and plasma, as well as
intact lenalidomide in plasma, the maximum concentra-
tions were achieved between 0.5 and 1 h postdose followed
by similar rates of elimination, with the levels below the
limits of quantitation by 24 h postdose. The distribution of
radioactivity into erythrocytes averaged from 44 to 36% of
the whole blood radioactivity from 0.25 to 12 h postdose.
These values were comparable to the mean hematocrit
(42–43%) for these subjects. The pharmacokinetic param-
eters for the total radioactivity in both plasma and whole
blood are comparable to that for the parent. Based on the
ratio of AUC? for lenalidomide and total radioactivity in
plasma, lenalidomide comprised 98% of Cmax and 92% of
AUC for the total plasma radioactivity. The mean renal
clearance was estimated to be 261 ± 30 mL/min based on
the amount of radioactive equivalents recovered in urine
and the radioactive plasma AUC from 0 to 12 h postdose.
The mean radioactive concentration in semen collected
between 2 and 3 h postdose was 492 ± 20.7 ngEq/g and
similar to the radioactive Cmax equivalent observed in
plasma. The semen concentration of radioactivity at 72 h
time point was 31.7 ± 5.6 ngEq/g.
Metabolite identiﬁcation
The plasma and urinary radioactivity were composed of a
predominant peak, two small peaks (Metabolites A and B)
and a few very minor peaks. A representative chromato-
gram is shown in Fig. 3.
Identiﬁcation of the predominant component
The HPLC retention time of the predominant peak in both
urine and plasma corresponded with that of lenalidomide
standard. The protonated molecular ion with an m/z 260
[M ? H]
? and the product ions of m/z 187, m/z 149, m/z
106 and m/z 84 were observed with both lenalidomide
standard and the predominant peak. Further, neutral losses
73 (corresponding to urea) and 111 (corresponding to
glutarimide ring) were also similar. The results of these
experiments conﬁrm the identiﬁcation of the predominant
peak of plasma and urinary radioactivity as unchanged
lenalidomide.
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Fig. 2 Cumulative radioactivity recovery in urine, feces and all
excreta over 10 days following a single oral 25 mg dose of [
14C]-
lenalidomide in healthy male subjects. Shown are mean ± SD
(N = 6)
Table 1 Total recovery of radioactivity from excreta
Subject % of administered dose
Urine Feces Semen Total
0001 87.00 7.190 0.0050 94.20
0002 88.83 1.690 0.0080 90.53
0003 92.08 3.390 0.0040 95.47
0004 87.40 3.830 0.0070 91.24
0005 92.17 5.040 0.0040 97.21
0006 94.55 2.580 0.0090 97.14
Mean 90.30 3.95 0.0062 94.30
SD 3.04 1.94 0.0021 2.88
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123Identiﬁcation of metabolite A
The protonated molecular ion of Metabolite A of both
plasma and urine was m/z 276. The results of the neutral loss
experiment showed m/z 111 amu (corresponding to
unchanged glutarimide moiety) and 73 amu (corresponding
to urea moiety as observed in parent), indicating that the
glutarimide moiety is intact in Metabolite A. A product ion
scan for m/z 276 yielded m/z 165, which is indicative of
hydroxylation of the iso-indolinone portion of the molecule
(Fig. 4). The retention time and fragmentation pattern of
this metabolite were similar to that of the synthetic standard
of 5-hydroxy-lenalidomide (Fig. 4). Metabolite A had an
accurate mass of m/z 276.09765, which suggests the addi-
tion of an oxygen atom (16 amu) to the parent molecular ion
(lenalidomide m/z 260.10263). Metabolite A and synthetic
standard 5-OH-lenalidomide were combined for concurrent
analysis to further conﬁrm the consistency of the retention
time. Metabolite A and 5-OH-lenalidomide standard eluted
as one peak with an m/z 276.09741 conﬁrming the structure
of Metabolite A as 5-OH-lenalidomide (Fig. 1).
Identiﬁcation of metabolite B
The protonated molecular ion of Metabolite B from both
plasma and urine was observed at m/z 302, which is
42 amu greater than the parent, and two major fragments
with m/z 229.1 and m/z 191.3. Metabolite B resulted in
neutral losses of 73 and 111 (corresponding to urea and
glutarimide ring), suggesting unchanged glutarimide moi-
ety in Metabolite B. A synthetic standard N-acetyl-lena-
lidomide produced a similar fragmentation pattern as for
Metabolite B and had an identical HPLC retention time,
conﬁrming Metabolite B as N-acetyl-lenalidomide (Fig. 1).
Plasma metabolite proﬁling
Lenalidomide was the predominant circulating component
of the radioactivity in the pooled plasma samples (Fig. 5).
In addition, two metabolites in plasma were 5-OH-lenlid-
omide and N-acetyl-lenalidomide, representing 2.9 and
4.2% of lenalidomide levels, respectively. Both metabolites
Table 2 Summary of pharmacokinetic parameters
Plasma Radioactivity
Lenalidomide Plasma Whole blood
Tmax (h) 1.00 (0.50–1.02) 0.77 (0.50–1.02) 0.77 (0.50–1.02)
Cmax (ng/ml)
a 413 ± 77 420 ± 65 404 ± 62
AUCt (h ng/ml)
b 1,248 ± 133 1,340 ± 143 1,246 ± 125
AUC? (h ng/ml)
b 1,319 ± 162 1,428 ± 168 1,329 ± 149
t1/2 (h) 2.78 ± 0.40 2.97 ± 0.36 3.05 ± 0.38
CL/F (ml/min) 318 ± 41 294 ± 35 NC
V/F (l) 75.8 ± 7.3 75.1 ± 10.6 NC
Cmax ratio
c 0.983 ± 0.074 NA 0.963 ± 0.028
AUC? ratio
c 0.923 ± 0.017 NA 0.931 ± 0.020
Means ± SD (N = 6) are presented for all parameters except that median
(range) data are presented for Tmax
NA not applicable, NC not calculated
a Expressed as ngEq/ml for plasma radioactivity and as ngEq/g for whole
blood radioactivity
b Expreseed as h ngEq/ml for plasma radioactivity and as h ngEq/g for whole
blood radioactivity
c Ratio to plasma radioactivity
Fig. 3 Representative radio-
chromatogram of an 0–4 h urine
sample following a single oral
25 mg dose of [
14C]-
lenalidomide in a healthy male
subject
794 Cancer Chemother Pharmacol (2012) 69:789–797
123appeared to have an elimination rate similar to lenalido-
mide (Fig. 5).
Urinary metabolite proﬁling
Unchanged lenalidomide accounted for a predominant por-
tion of the radioactivity in urine, with minor amounts of
5-OH-lenalidomide and N-acetyl-lenalidomide. The total
radioactivity, lenalidomide, 5-OH-lenalidomide and
N-acetyl-lenalidomideinurineupto24 hwere88.5 ± 3.60,
81.74 ± 3.61, 4.03 ± 0.92 and 1.24 ± 0.92% of the
administered dose, respectively. Lenalidomide represented
92% of the total radioactivity in the proﬁled urine samples.
5-OH-lenalidomide and N-acetyl-lenalidomide were
approximately 4.9 and 1.5% of the lenalidomide level.
Fecal metabolite proﬁling
Radioactivity in fecal samples composed of eight peaks,
including unchanged lenalidomide, 5-OH-lenalidomide,
N-acetyl-lenalidomide and a few other minor unidenti-
ﬁed metabolites. None of the peaks, including parent,
represented a predominant portion of the fecal radio-
activity or accounted for greater than 1% of the total
dose. The total radioactivity, lenalidomide, 5-OH-lena-
lidomide, and N-acetyl-lenalidomide in the proﬁled
fecal samples were 3.89 ± 1.95, 0.45 ± 0.24,
0.56 ± 0.21 and 0.59 ± 0.46% of the administered
dose, respectively. Overall, fecal route of elimination is
not an important clearance mechanism for lenalidomide
in humans.
Fig. 4 Identiﬁcation of metabolite A: a Mass spectrum of 5-hydroxy-
lenalidomide synthetic standard. b Mass spectrum of metabolite A
isolated from urine. c Radio-chromatogram of metabolite A isolated
from urine. d Mass fragments of 5-hydroxy-lenalidomide synthetic
standard. e Mass fragments of metabolite A isolated from urine.
f Proposed fragmentation pattern of metabolite A
Cancer Chemother Pharmacol (2012) 69:789–797 795
123Semen radioactivity proﬁling
The 2–3 h semen samples, which represented 0.0059% of
the radioactive dose, was composed of lenalidomide (rep-
resenting approximately half of the total sample radioac-
tivity) and multiple peaks including 5-hydroxy-
lenalidomide, N-acetyl-lenalidomide and some very minor
unidentiﬁed metabolites. The 72 h semen sample had very
low radioactivity levels to allow for proﬁling.
Discussion
Basedontheextentofurinaryrecoveryofradioactivity(90%
of dose), it can be concluded that the absorption of lenalid-
omide (at least 90% of the dose absorbed) is very high in
humans following oral administration. Further, based on the
82% of the dose excreted in intact form in urine within 24 h
postdose, the oral bioavailability of lenalidomide is at least
82% in humans. Both lenalidomide and the [
14C]-radioac-
tivity were rapidly absorbed into the circulation, with the
median Tmax ranging from 0.77 to 1 h postdose. The
absorption rate for the suspension is similar to that for the
capsule formulation (Tmax = 0.75–0.88 h) [17]. A compar-
ison of the exposure parameters for lenalidomide and total
radioactivity in plasma indicate that unchanged lenalido-
mide is the predominant circulating component.
The whole blood-to-plasma radioactivity exposure lev-
els were comparable, and the percent radioactivity dis-
tributed into red blood cells (44–36%) approximated the
mean hematocrit value (41–43%). These data suggest that
lenalidomide, as the primary radioactive component in
circulation, is distributed nearly equally between cellular
and plasma components of whole blood. This observation,
along with similar pharmacokinetic proﬁles for whole
blood and plasma radioactivity, demonstrates that plasma is
a suitable matrix for the representation of lenalidomide
concentrations and exposure in whole blood.
The present study suggests that lenalidomide and its
metabolites were distributed into human semen. However,
the total radioactivity found in semen accounted only for a
minuscule percentage of the administered dose (0.0062%;
1.5 lgEq of lenalidomide). The extent of excretion of le-
nalidomide in semen was conﬁrmed in another clinical
study following multiple oral doses of lenalidomide to
healthy men;\0.01% of dose excreted in semen at steady
state [17]. Lenalidomide is an analog of thalidomide and
has demonstrated teratogenic effects in monkeys [18]. The
possible transfer of lenalidomide to a female partner via
semen during a heterosexual intercourse with a male on
lenalidomide therapy is a concern. Results of both studies
suggest that the exposure of lenalidomide to an embryo or
fetus in case of nonprotected sexual intercourse between
male patient and female partner would be four orders of
magnitude lower than the plasma exposure in the treated
male subjects.
Total recovery of the [
14C]-radioactivity averaged
94.3% of the administered dose, with mean contributions
of 90.3, 3.95 and 0.0062% from urine, feces and semen,
respectively. Further, the elimination of [
14C]-radioactivity
was rapid as demonstrated by a relatively short half-life
(approximately 3 h) in circulation and a majority (88%) of
the radioactivity was recovered within the ﬁrst 24 h after
dosing. The estimation for urinary excretion (82% of the
dose) of the unchanged lenalidomide following a radioac-
tive suspension dose is consistent with the previous ﬁnd-
ings with the capsule formulation (84% of the dose) [15].
In patients with decreased renal function, renal lenalido-
mide clearance decreased substantially, prolonging its half-
life by approximately 6–12 h and increasing plasma
exposure by two- to four-fold [15]. Therefore, dose mod-
iﬁcations for patients with renal impairment have been
implemented [13]. With careful monitoring of renal func-
tion and adverse events, and with appropriate dose
adjustments, lenalidomide is well tolerated in MM patients
with renal impairment [19].
Mean renal clearance (260 ml/min) of the plasma
radioactivity was nearly two-fold greater than the normal
glomerular ﬁltration rate (125 ml/min), suggesting that
renal elimination likely includes both passive and active
processes. An in vitro study demonstrated that lenalido-
mide is a weak substrate of P-glycoprotein, but not a
substrate of human organic anionic transporters OAT1/
OAT3, human cationic transporter OCT1 and human
organic anion transporting polypeptide OATP2 [20]. If
there is an active secretion component in the renal excre-
tion of lenalidomide, it is not known which renal trans-
porter(s) may be responsible.
Time postdose (hours)
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Fig. 5 Concentrations or equivalents versus time proﬁle for radioac-
tivity, lenalidomide and its metabolites in inter-subject pooled plasma
samples
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123Unchanged lenalidomide is the predominant component
of both circulating and excreted radioactivity in humans.
Two metabolites, resulting from hydroxylation at the 5
position of the amino-iso-indolinone moiety and N-acety-
lation, each represented less than 5% of both total radio-
activity and unchanged lenalidomide levels in circulation
as well as excreta. Based on the results of in vitro phar-
macological assays, both of these metabolites are not
expected to contribute to the therapeutic activity of lena-
lidomide (Personal Communication, Dr. P. Schafer, Cel-
gene). Overall, metabolism contributes to a very minor
extent to the clearance of lenalidomide in humans. These in
vivo results are consistent with in vitro studies that dem-
onstrated minimal ability of cytochrome P450 to metabo-
lize lenalidomide [16]. The data generated in this study
demonstrate that lenalidomide is not likely to be subject to
drug–drug interactions when coadministered with cyto-
chrome P450 inhibitors during polypharmacy.
In summary, following oral administration, lenalido-
mide is rapidly absorbed and highly bioavailable, metab-
olized minimally and eliminated predominantly via urinary
excretion in the unchanged form in humans.
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